Specify Company / Ticker to Get the Summary
Ikena Oncology Inc
IKNAIkena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. Address: 645 Summer Street, Boston, MA, United States, 02210
Analytics
WallStreet Target Price
3 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IKNA
Dividend Analytics IKNA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IKNA
Stock Valuation IKNA
Financials IKNA
Results | 2019 | Dynamics |